Literature DB >> 9285312

Efficacy of enalapril after ineffective theophylline treatment on erythrocytosis after renal transplantation.

T Yagisawa1, H Toma, H Yaguchi, M Tomaru, Y Iijima, H Suzuki, T Nakada.   

Abstract

Erythrocytosis represents a common complication in renal allograft recipients. Traditional therapies including phlebotomy and bilateral native nephrectomies are cumbersome for both the clinical personnel and the patient. Recently, pharmacological agents such as angiotensin converting enzyme inhibitor and theophylline have been proposed as effective therapies for post-transplant erythrocytosis (PTE). We have treated a PTE patient successfully with enalapril without any side effects and renal dysfunction after theophylline treatment showed no improvement in PTE. A decline in Ht levels was independent of the changes in Epo levels during enalapril treatment. Although the mechanism underlying the beneficial effect of enalapril remains undetermined, enalapril is recommended for the initial treatment of PTE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285312     DOI: 10.1007/bf02550937

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  15 in total

1.  Effects of enalapril on erythrocytosis after renal transplantation.

Authors:  R S Gaston; B A Julian; A G Diethelm; J J Curtis
Journal:  Ann Intern Med       Date:  1991-12-15       Impact factor: 25.391

2.  High haematocrit in haemodialysis patients can be controlled by theophylline administration.

Authors:  A Vereerstraeten; K Gastaldello; C Gervy; J L Vanherweghem; C Tielemans
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

Review 3.  Posttransplant erythrocytosis: an enigma revisited.

Authors:  R S Gaston; B A Julian; J J Curtis
Journal:  Am J Kidney Dis       Date:  1994-07       Impact factor: 8.860

4.  Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients.

Authors:  J M Aeberhard; P A Schneider; M B Vallotton; A Kurtz; M Leski
Journal:  Transplantation       Date:  1990-10       Impact factor: 4.939

5.  Anemia and angiotensin-converting enzyme inhibition in renal transplant recipients.

Authors:  P C Sizeland; R R Bailey; K L Lynn; R A Robson
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

6.  High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril.

Authors:  F Fyhrquist; K Karppinen; T Honkanen; O Saijonmaa; K Rosenlöf
Journal:  J Intern Med       Date:  1989-10       Impact factor: 8.989

7.  Erythrocytosis after renal transplantation. The response to theophylline treatment.

Authors:  Y Ilan; M Dranitzki-Elhallel; D Rubinger; J Silver; M M Popovtzer
Journal:  Transplantation       Date:  1994-03-15       Impact factor: 4.939

8.  Erythrocytosis after renal transplantation. A prospective analysis.

Authors:  N B Sumrani; P Daskalakis; A M Miles; S Sarkar; M S Markell; J H Hong; E A Friedman; B G Sommer
Journal:  ASAIO J       Date:  1993 Jan-Mar       Impact factor: 2.872

9.  Efficacy of captopril on posttransplant erythrocytosis. Long-term follow-up.

Authors:  J V Torregrosa; J M Campistol; M Montesinos; A G Rogada; F Oppenheimer; J Andreu
Journal:  Transplantation       Date:  1994-08-15       Impact factor: 4.939

10.  A1 and A2 adenosine receptor regulation of erythropoietin production.

Authors:  M Ueno; J Brookins; B Beckman; J W Fisher
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.